is a Managing Director in Cambridge, MA, USA.Prior to joining the fund, he worked at the Novartis Institutes for BioMedical Research as the Director of Special Projects. Campbell is a New Zealand-trained physician, Kauffman Fellow, and holds an MBA from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government, where he was a Knox Fellow and Rotary Ambassadorial Scholar. Campbell serves on the boards of Aerpio Therapeutics, Akebia Therapeutics, Alios BioPharm, Euthymics Biosciences, Galera, ImaginAB, Neurovance and Tokai Pharmaceuticals and as an observer on the board of Aileron Therapeutics.
Aerpio Therapeutics (Board Seat)
Akebia Therapeutics (Board Seat)
Alios BioPharma Inc. (Board Seat)
Euthymics Bioscience Inc. (Board Seat)
ImaginAb (Board Seat)
Neurovance (Board Seat)
Tokai Pharmaceuticals Inc. (Board Seat)